Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07806552
NA

Middle Meningeal Artery Embolization in Patients With Chronic Subdural Hematoma

Sponsor: Assiut University

View on ClinicalTrials.gov

Summary

Primary : to evaluate the efficacy of MMAE on resolution and recurrence of hematoma in patients with CSDH. Secondary : evaluate the effect of MMAE on functional outcome, radiological changes, the need to repeat surgery, duration of hospital stay, time for hematoma to resolve.

Official title: Impact of Middle Meningeal Artery Embolization on Recurrence and Functional Outcomes in Patients With Chronic Subdural Hematoma

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

35

Start Date

2026-09-01

Completion Date

2029-02-28

Last Updated

2026-09-08

Healthy Volunteers

No

Interventions

PROCEDURE

middle meningeal artery embolization

Middle meningeal artery (MMA) embolization is a minimally invasive endovascular procedure designed to treat chronic subdural hematomas by blocking blood flow to the MMA, preventing recurrent bleeding. Under local or general anesthesia, a catheter is inserted through a micro-puncture in the femoral or radial artery and navigated up to the external carotid system into the MMA under real-time fluoroscopic (X-ray) guidance. Angiography is performed to map the arterial anatomy and identify any dangerous anastomoses with the ophthalmic or internal carotid arteries. Once positioned safely, an embolic agent such as liquid embolic systems (e.g., Onyx, n-BCA), liquid-suspended microparticles (PVA), or microcoils is injected into the anterior and posterior branches of the MMA. This occludes the fragile, hypervascular membranes driving the hematoma, allowing the body to naturally reabsorb the collected blood and reducing the need for open surgical evacuation.